Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in
drug-delivery platforms focused on its patented DehydraTECH-based,
drug-delivery technology and formulation development. A recent article
discussing the company reads, “Earlier this year, Lexaria moved into its new
head office that includes a Health Canada-licensed research and development
laboratory that is being used to conduct world-leading research into
drug-delivery methods and improvements. In addition to accelerating research in
the company’s DehydraTECH drug-delivery platform, Lexaria is also considering
issuing a limited commercial release of DehydraTECH version 2.0, which has been
shown to deliver 811% more CBD into animal blood than generic industry control
formulations, the company stated in an update to shareholders (http://ibn.fm/cWL3T). . . .
Lexaria’s focus on pioneering new technologies that can more efficiently
deliver APIs into the bloodstream, where they can have their desired effect,
includes developing an effective way to cross the blood-brain-barrier.
Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing
indicated 1,937% more CBD reached animal brain tissue compared to generic
industry control formulations.”
To view the full article, visit http://ibn.fm/YBVxA
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
